VORAXAZE

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Romania, Spain.

Active ingredients

The drug VORAXAZE contains one active pharmaceutical ingredient (API):

1	Glucarpidase UNII 2GFP9BJD79 - GLUCARPIDASE
	Glucarpidase is a recombinant bacterial enzyme that hydrolyses the carboxyl-terminal glutamate residue from folic acid and structurally related molecules such asMTX. Glucarpidase converts MTX to its inactive metabolites DAMPA and glutamate.
	Read more about Glucarpidase

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VORAXAZE Powder for solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)
VORAXAZE Powder for solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V03AF09	Glucarpidase	V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AF Detoxifying agents for antineoplastic treatment
Discover more medicines within V03AF09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1614136, 1873672
ES	Centro de información online de medicamentos de la AEMPS	1211586001
FR	Base de données publique des médicaments	60176597
IT	Agenzia del Farmaco	049882018
LT	Valstybinė vaistų kontrolės tarnyba	1093991
PL	Rejestru Produktów Leczniczych	100467617
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69225001
US	FDA, National Drug Code	50633-210